New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo’s Ozempic and Wegovy.
Source: US Top News and Analysis
Related Posts
36-year-old left the U.S. for China—now pays $1,000 rent and $100 for groceries for family of 4: It’s my ‘version of the American Dream’
A decade ago, Bradley Krae left the United States to teach English in Shenzhen, China.…
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo…
Fast Retailing shares soar to record high after the Uniqlo owner lifts profit forecast
Shares of Fast Retailing surged over 9% to a record high on Friday after the…